Table 3.
Changes in antioxidant capacity and oxidation markers in women with metabolic syndrome after agraz consumption compared to placebo.
| Variables | Placebo | Agraz | Δ (Agraz-Placebo) | p | ||
|---|---|---|---|---|---|---|
| n | Mean or Median ± SD or IQR (p25-p75) |
n | Mean or Median ± SD or IQR (p25-p75) |
Mean or Median ± SD or IQR (p25-p75) |
||
| DPPH (% Scavenging effect) a | 40 | 10.55 ± 6.19 | 40 | 12.63 ± 7.47 | 2.08 ± 5.75 | 0.028 * |
| Total phenols mgGA/L b | 40 | 297.29 (57.29) | 40 | 331.88 (56.04) | 7.92 (72.70) | 0.279 |
| TBARS b | 40 | 0.89 (0.39) | 40 | 0.92 (0.45) | 0.04 (0.42) | 0.402 |
| F2-Isoprostanes (ng/mg creatinine) b | 35 | 2.86 (3.97) | 35 | 3.03 (3.41) | 0.11 (3.39) | 0.863 |
| OHdG (ng/mg creatinine) a | 35 | 1.97 ± 0.66 | 35 | 1.66 ± 0.5 | −0.27 ± 0.72 | 0.041 * |
a Paired T; b Wilcoxon; SD: Standard deviation; IQR: Interquartile range; * Significance p ≤ 0.05. DPPH: 2,2-Diphenyl-1-Picrylhydrazyl; TBARS: Thiobarbituric acid reactive substances; 8-OHdG: 8-hydroxy-2′-deoxyguanosine.